Alivus Life Sciences Ltd vs Ind Swift Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 13 Apr 15:30 . The P/E Ratio of Alivus Life Sciences Ltd is 0 as of March 2022 .The P/E Ratio of Ind-Swift Ltd is 0 as of March 2022 . The Market Cap of Alivus Life Sciences Ltd is ₹ 0 crore as of March 2022 .The Market Cap of Ind-Swift Ltd is ₹ 60.61 crore as of March 2022 . The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Ind-Swift Ltd for the Mar '25 is ₹ 426.19 crore as compare to the Dec '24 revenue of ₹ 122.96 crore. This represent the growth of 246.61% The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Ind-Swift Ltd for the Mar '25 is ₹ 278.4 crore as compare to the Dec '24 ebitda of ₹ 9.98 crore. This represent the growth of 2689% The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of 0.0% The net profit of Ind-Swift Ltd changed from ₹ 28.24 crore to ₹ 256.6 crore over 4 quarters. This represents a CAGR of 808.64% The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Ind-Swift Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Ind-Swift Ltd

Ind-Swift Limited (ISL) is an India-based pharmaceutical company.
The Company is engaged in the manufacturing and marketing of pharmaceutical finished dosage.
The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables.
The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.

FAQs for the comparison of Alivus Life Sciences Ltd and null

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Ind-Swift Ltd?

Market cap of Alivus Life Sciences Ltd is 13,788 Cr while Market cap of Ind-Swift Ltd is 85 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Ind-Swift Ltd?

The stock performance of Alivus Life Sciences Ltd and Ind-Swift Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Ind-Swift Ltd?

As of May 6, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1123.45. On the other hand, Ind-Swift Ltd stock price is INR ₹15.7.

How do dividend payouts of Alivus Life Sciences Ltd and Ind-Swift Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Ind-Swift Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.